Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older
• People who are willing to take part voluntarily and sign a consent form
• People who have a solid tumour cancer that has been confirmed through a tissue or cell sample, who are currently receiving or have completed cancer treatment, and whose cancer has not significantly worsened in the 28 days before the first dose. The treating doctor must also estimate that a change in cancer treatment will not be needed during the first 21 days of the study. For the second part of the trial, specific cancer types are grouped into cohorts: colorectal cancer patients currently on or about to start second-line treatment (no more than 5 cycles completed, and not suitable for immune checkpoint inhibitor therapy); pancreatic cancer patients currently on or about to start first-line treatment (no more than 3 cycles completed, and not suitable for targeted therapy); or patients with other solid tumour cancers currently receiving or having completed standard treatment (no more than three prior lines of treatment)
• People diagnosed with cancer cachexia (significant unintended weight loss related to cancer), meaning they have lost more than 5% of their body weight within the last 6 months, or more than 2% if their Body Mass Index (a measure of body weight relative to height) is below 18.5 — with prior weight records supported by written documentation
• People whose organs (such as kidneys, liver, and blood cells) are functioning well enough to meet the study's laboratory test requirements, without having received blood transfusions or growth factor support in the 14 days before testing
• People with a physical functioning score (a standard medical measure of how well a person can carry out daily activities) of 1 or lower for part of the study, or 2 or lower for another part (confirm with trial site which applies)
• People expected to live for at least 4 months
• People who are capable of having children and who agree to use adequate contraception from the time of signing the consent form until 6 months after the last dose; women of childbearing age must also have a negative pregnancy blood test within 7 days before the first dose

Who may not be able to join:

• People whose reduced food intake has a reversible or treatable cause
• People who have difficulty swallowing or absorbing food, including those with a blocked bowel, active inflammatory bowel disease, or short bowel syndrome
• People whose weight loss is clearly caused by something other than cancer, such as severe chronic lung disease, uncontrolled thyroid problems, failure of a vital organ, or AIDS
• People who are receiving tube feeding or nutrition delivered directly into the bloodstream during the screening period
• People who have taken any prescription medication intended to improve appetite or prevent weight loss within 28 days (or 5 half-lives, whichever is shorter) before the first dose — including but not limited to anamorelin, medroxyprogesterone acetate, dronabinol, or medical marijuana
• People who have started high-dose steroid medication (prednisone above 10 mg per day or an equivalent dose of a similar drug) or other immune-suppressing treatments within 28 days before the first dose, not counting steroids used as part of cancer treatment preparation
• People with a Body Mass Index above 30
• People who have had major surgery within 4 weeks before the first dose and have not yet recovered, or who are expected to have major surgery during the study
• People who have taken another experimental drug as part of a different clinical study within 4 weeks or 5 half-lives (whichever is shorter) before the first dose
• People who have a serious infection requiring intravenous antibiotics, antiviral, or antifungal treatment during the screening period
• People who have had hard-to-control moderate or large fluid build-up around the heart, lungs, or abdomen within 14 days before the first dose
• People who have had a second, separate active cancer within the 2 years before the first dose — except for certain localised cancers that have been fully treated, such as some skin cancers, superficial bladder cancer, or early-stage breast cancer
• People with active cancer spread to the brain or nervous system, unless imaging taken within 28 days before the first dose confirms the affected areas are stable and under control
• People with a history of serious heart conditions, including dangerous heart rhythm problems, significant blockages in the heart's electrical system, a heart attack, heart failure, stroke, or other serious heart events within 6 months before the first dose, or poor overall heart function
• People with a serious immune system deficiency or a history of organ transplantation
• People who have experienced depression or thoughts of suicide or self-harm recently (within the past year) or currently
• People with a known allergy to the study drug JMT203 or any of its ingredients
• People with a history of severe allergic reactions or uncontrollable allergic asthma
• People whom the treating doctor considers unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.